Related Experiment Video
Updated: May 14, 2026

Isolation and Enrichment of Human Lung Epithelial Progenitor Cells for Organoid Culture
Published on: July 21, 2020
Separation of Human P63+ Lung Progenitor Cells from Growth-Arrested Feeders Using Multidimensional Double Spiral
Weilu Huang1, Xuxia Zhu2, Lanlan Zhu1
1Jiangxi Provincial Key Laboratory of Respiratory Diseases, Jiangxi Institute of Respiratory Disease, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330209, China.
Abstract:
Recent clinical trials have highlighted the potential of P63+ lung progenitor cell (LPC) transplantation for lung repair and regeneration. Currently, ex vivo P63+ LPC expansion depends on coculture with growth-arrested fibroblast feeder cells (GAFs), necessitating repeated purification during passaging. While differential enzymatic digestion (DED) and fluorescence- or magnetic-activated cell sorting techniques (FACS/MACS) offer partial solutions, a scalable, efficient, and consistent separation technique remains unmet, particularly for cell therapy manufacturing. Here, we present a multidimensional double spiral (MDDS) inertial microfluidic device designed for high-throughput label-free enrichment of P63+ LPCs. The MDDS device achieves cell size-based separation of P63+ LPCs and growth-arrested feeder cells, processing at a rate of 106 to 107 cells per minute. MDDS-sorted P63+ LPC purity correlates with the LPC-to-GAF ratio in culture. With an initial ratio >1:1, it yields P63+ LPC purity exceeding 80%. Moreover, the device consistently recovers >80% of P63+ LPCs, with the unrecovered fraction enriched in senescent cells exhibiting compromised clonogenicity and differentiation capacity. In direct benchmarking against DED and FACS, the MDDS device delivered a balanced performance in terms of purity and recovery, while offering advantages in throughput, consistency, and scalability. We propose that this technology could enable more consistent and efficient enrichment of feeder-cultured P63+ LPCs, thereby supporting more robust clinical manufacturing processes.

